{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002427","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.279654+00:00","generated_at":"2026-06-03T03:42:30.974407+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Aptose Biosciences amends employment agreements with CEO, CMO, and CFO to harmonize change of control provisions","bullets":["CEO William Rice's base salary increased to $648,960, with bonus up to 55% of base and auto allowance of $18,000.","CMO Rafael Bejar's salary increased to $509,600, added Senior VP title, and updated severance for change of control.","CFO Fletcher Payne's salary increased to $479,440, added Chief Business Officer and Corporate Secretary titles.","Each amendment harmonizes change of control provisions and updates compensation terms for the three executives."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002427","json":"https://secwatch.observer/filing/0001171843-24-002427.json","markdown":"https://secwatch.observer/filing/0001171843-24-002427.md","text":"https://secwatch.observer/filing/0001171843-24-002427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002427/0001171843-24-002427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002427/f8k_050124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:42:30.974407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"079de0ad85","claim":"Rafael Bejar was appointed as Senior Vice President and Chief Medical Officer at Aptose Biosciences Inc..","evidence_excerpt":"The amendment also added the title of Senior Vice President to Mr. Bejar’s position,","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002427/0001171843-24-002427-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President and Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"57c6092a49","claim":"Fletcher Payne was appointed as Senior Vice President, Chief Financial Officer, Chief Business Officer, and Corporate Secretary at Aptose Biosciences Inc..","evidence_excerpt":"The amendment also added the titles of Chief Business Officer and Corporate Secretary to Mr. Payne’s position.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184324002427/0001171843-24-002427-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer, Chief Business Officer, and Corporate Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}